不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双重难治性慢性淋巴细胞白血病：临床情景与治疗策略
英文原题：Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies.
查看英文原题
Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
慢性淋巴细胞白血病（CLL）在多数患者中病程通常惰性，但仍可能复发，或对常用的两大类药物——共价BTK抑制剂和BCL2抑制剂——产生耐药。本综述概述停用这两类药物的可能原因，界定双药暴露（DE）和双重耐药（DR）的概念，阐明可能导致DR的治疗序列，总结这一患者亚组的不良预后，并介绍其管理中已获批、在研及效果相对欠佳的治疗选择。最后，文章提供3个DE/DR CLL患者的临床案例，包括病例分析和实用管理建议，并总结教学要点。
展开英文摘要原文
Despite its typically indolent course in most patients, chronic lymphocytic leukemia (CLL) can relapse or become refractory to the two main classes of drugs commonly used: covalent BTK inhibitors and BCL2 inhibitors.
This review outlines the potential reasons for discontinuation of these drug classes, defines the concepts of double exposure (DE) and double refractoriness (DR), delineates the possible treatment sequences leading to DR, summarizes the poor prognosis of this patient subgroup, and describes the approved, investigational, and less optimal therapeutic alternatives for the management of this population.
Finally, three illustrative clinical vignettes of patients with DE/DR CLL are presented, including case analysis and practical management recommendations, as well as teaching points.
论文信息
- 作者
- Mozas P、Quintela D、Serna Á、en representación de Nexo en LLC
- 单位
- Servicio de Hematología, Hospital Clínic de Barcelona e Institut d'Investigacions August Pi i Sunyer, Barcelona, España. Electronic address: mozas@clinic.cat.Spain
- 文献类型
- 综述
- 期刊
- Medicina clinica2026 Jan
- 原文标识
- PubMed 41538902 · DOI 10.1016/j.medcli.2025.107288